These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 24794308)

  • 1. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
    Lacouture ME; Davis ME; Elzinga G; Butowski N; Tran D; Villano JL; DiMeglio L; Davies AM; Wong ET
    Semin Oncol; 2014 Jun; 41 Suppl 4():S1-14. PubMed ID: 24794308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NovoTTF-100A: a new treatment modality for recurrent glioblastoma.
    Fonkem E; Wong ET
    Expert Rev Neurother; 2012 Aug; 12(8):895-9. PubMed ID: 22708931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
    Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
    Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study.
    Chaudhry A; Benson L; Varshaver M; Farber O; Weinberg U; Kirson E; Palti Y
    World J Surg Oncol; 2015 Nov; 13():316. PubMed ID: 26558989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.
    Turner SG; Gergel T; Wu H; Lacroix M; Toms SA
    World J Surg Oncol; 2014 May; 12():162. PubMed ID: 24884522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes.
    Rehman AA; Elmore KB; Mattei TA
    Neurosurg Focus; 2015 Mar; 38(3):E14. PubMed ID: 25727223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor treating fields: a new frontier in cancer therapy.
    Davies AM; Weinberg U; Palti Y
    Ann N Y Acad Sci; 2013 Jul; 1291():86-95. PubMed ID: 23659608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
    Stupp R; Wong ET; Kanner AA; Steinberg D; Engelhard H; Heidecke V; Kirson ED; Taillibert S; Liebermann F; Dbalý V; Ram Z; Villano JL; Rainov N; Weinberg U; Schiff D; Kunschner L; Raizer J; Honnorat J; Sloan A; Malkin M; Landolfi JC; Payer F; Mehdorn M; Weil RJ; Pannullo SC; Westphal M; Smrcka M; Chin L; Kostron H; Hofer S; Bruce J; Cosgrove R; Paleologous N; Palti Y; Gutin PH
    Eur J Cancer; 2012 Sep; 48(14):2192-202. PubMed ID: 22608262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
    Wong ET; Lok E; Swanson KD
    Cancer Med; 2015 Mar; 4(3):383-91. PubMed ID: 25620708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post Hoc analyses of intention-to-treat population in phase III comparison of NovoTTF-100A™ system versus best physician's choice chemotherapy.
    Kanner AA; Wong ET; Villano JL; Ram Z;
    Semin Oncol; 2014 Oct; 41 Suppl 6():S25-34. PubMed ID: 25213871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed response and survival from NovoTTF-100A in recurrent GBM.
    Villano JL; Williams LE; Watson KS; Ignatius N; Wilson MT; Valyi-Nagy T; Michals EA; Engelhard HH
    Med Oncol; 2013 Mar; 30(1):338. PubMed ID: 23307238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skin toxicities associated with tumor treating fields: case based review.
    Lukas RV; Ratermann KL; Wong ET; Villano JL
    J Neurooncol; 2017 Dec; 135(3):593-599. PubMed ID: 28849343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
    Vymazal J; Wong ET
    Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma.
    Lacouture ME; Anadkat MJ; Ballo MT; Iwamoto F; Jeyapalan SA; La Rocca RV; Schwartz M; Serventi JN; Glas M
    Front Oncol; 2020; 10():1045. PubMed ID: 32850308
    [No Abstract]   [Full Text] [Related]  

  • 15. A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: introducing a novel modality, TTFields.
    Butowski N; Wong ET; Mehta MP; Wilson LK
    Semin Oncol; 2013 Dec; 40(6):S2-4. PubMed ID: 24331200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma.
    Wong ET; Lok E; Swanson KD; Gautam S; Engelhard HH; Lieberman F; Taillibert S; Ram Z; Villano JL
    Cancer Med; 2014 Jun; 3(3):592-602. PubMed ID: 24574359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations.
    Lok E; Swanson KD; Wong ET
    Expert Rev Med Devices; 2015; 12(6):717-26. PubMed ID: 26513694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.
    Mittal S; Klinger NV; Michelhaugh SK; Barger GR; Pannullo SC; Juhász C
    J Neurosurg; 2018 Feb; 128(2):414-421. PubMed ID: 28298023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors.
    Salzberg M; Kirson E; Palti Y; Rochlitz C
    Onkologie; 2008 Jul; 31(7):362-5. PubMed ID: 18596382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Treating Fields: Nursing Implications for an Emerging Technology
.
    Chang A
    Clin J Oncol Nurs; 2017 Jun; 21(3):302-304. PubMed ID: 28524900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.